BRIDGEWAY CAPITAL MANAGEMENT, LLC

Position in ACRV — Acrivon Therapeutics, Inc.

CIK 1107261 HOUSTON, TX

Position in ACRV

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$674,442

+$453,571 QoQ

Shares Held

378,900

+138.5% QoQ

Ownership

0.884%

of shares outstanding

% of Portfolio

0.01%

of 13F equity value

Holder Rank

of 46 holders

Holding Since

Dec 2023

11 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

BRIDGEWAY CAPITAL MANAGEMENT, LLC holds $87,985,615 across 108 Biotechnology names. ACRV ranks #27 (0.8% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	GLUE	Monte Rosa Therapeutics, Inc.	552,566	$13,372,097
2	INVA	Innoviva, Inc.	350,253	$7,954,245
3	PBYI	Puma Biotechnology, Inc.	791,616	$6,420,005
4	RIGL	Rigel Pharmaceuticals Inc	124,184	$4,858,078
5	EXEL	Exelixis, Inc.	66,100	$3,596,501
6	CRMD	CorMedix Inc.	434,132	$3,407,936
7	KROS	Keros Therapeutics, Inc.	265,017	$2,835,681
8	PTCT	Ptc Therapeutics, Inc.	22,000	$1,794,540

11 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$674,442	378,900	+138.5%	Shares	Sole	2026-08-14
2026-03-31	$220,871	158,900	+270.4%	Shares	Sole	2026-05-15
2025-12-31	$103,389	42,900	+87.3%	Shares	Sole	2026-02-17
2025-09-30	$41,449	22,900	0.0%	Shares	Sole	2025-11-14
2025-06-30	$27,251	22,900	-70.6%	Shares	Sole	2025-08-14
2025-03-31	$158,137	77,900	+4.4%	Shares	Sole	2025-05-15
2024-12-31	$449,092	74,600	-3.1%	Shares	Sole	2025-02-14
2024-09-30	$538,867	76,981	+32.3%	Shares	Sole	2024-11-14
2024-06-30	$337,449	58,181	0.0%	Shares	Sole	2024-08-14
2024-03-31	$415,994	58,181	+81.9%	Shares	Sole	2024-05-15
2023-12-31	$157,346	31,981	—	Shares	Sole	2024-02-14
No filing history on record for this holder in this stock.